2Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology, 1999, 117: 619-625.
3Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titer predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatpol, 1999, 30: 715-721.
4Segovia R, SanchezFueyo A, Rimola A, et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl, 2001, 7:106-112.
5Vargas V, Comas P, Castella L, et al. Incidence and outcome of hepatitis C virus infection after liver transplantation. Tanspl Int, 1994, (Suppl 1): S216-S220.
6Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg, 1999, 5: 491-496.
7Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology, 1998, 28: 585-589.
8Marzan A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol, 2001, 34: 903-910.
9Ishitani M. HBV vaccination and liver transplantation for hepatitis B: winning by recruiting from within? Liver Transpl, 2000, 6: 659-661.
10BenAri Z, Shmueli D, Shapira Z, et al. Loss of serum HBsAg after interferon-α therapy in liver transplant patients with recurrent hepatitis-B infection. Liver Transpl Surg, 1997, 3: 394-397.
